This AML-MR group corresponds to 3 separate AML entities in the ICC: those defined by MR gene mutations (with or without MR cytogenetics abnormalities), MR cytogenetic abnormalities (without MR gene mutations), or mutated TP53 (mono- or bi-allelic, and with VAF ≥10%, since the vast majority of TP53-mutated AML cases have complex karyotype that qualifies for AML-MR per WHO-HAEM5). Here, TP53 is linked to acute myeloid leukemia.